Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.54 |
| ▸ | TP53BP1 | Q12888 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.46 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL29031103 | 0.97 | HRH4 (0.51) | HRH4TP53BP1MEN1GLAGAA | |
| SCHEMBL15511394 | 0.88 | HRH4 (0.54) | HRH4TP53BP1MEN1GLAGAA | |
| SCHEMBL2533014 | 0.85 | ALDH1A1 (0.51) | HRH4MEN1GAAKMT2AKDM4E | |
| SCHEMBL10098376 | 0.84 | KDM4E (0.50) | HRH4TP53BP1MEN1GAAKMT2A | |
| SCHEMBL18135117 | 0.84 | HRH4 (0.50) | HRH4TP53BP1MEN1GLAGAA | |
| SCHEMBL31704499 | 0.84 | MAPT (0.50) | TP53BP1MEN1GAAKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL14876289 | 0.83 | KDM4E (0.49) | HRH4TP53BP1MEN1GAAKMT2A | |
| SCHEMBL14882840 | 0.82 | HRH4 (0.49) | HRH4TP53BP1MEN1GLAGAA | |
| SCHEMBL10098367 | 0.81 | KMO (0.57) | MEN1GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL28544347 | 0.80 | HRH4 (0.48) | HRH4TP53BP1MEN1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161649-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20210346395-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210346395-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-11 | — | — | US | disclosed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| CN-112513030-A | Quinoline derivatives as tyrosine kinase inhibitors | 里格尔药品股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851093-B2 | Tyrosine kinase inhibitors | TYRO3, RET, AXL | HRH4 883/4885TP53BP1 1657/4885MEN1 1216/4885 |
| US-12161649-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | HRH4 945/4885TP53BP1 564/4885MEN1 3498/4885 |
| US-20210346395-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HRH4 945/4885TP53BP1 564/4885MEN1 3498/4885 |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | HRH4 223/4885TP53BP1 2839/4885MEN1 2367/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | HRH4 883/4885TP53BP1 1657/4885MEN1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.